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                       INTRODUCTION
Preeclampsia is a multisystem disorder of pregnancy and puerperium of unknown 
aetiology and characterised  by  Hypertension  and Proteinuria.  It  is  one  of  the major 
causes  of  maternal  and perinatal  mortality  and morbidity.  It  complicates  5  –  8% of 
pregnancies.
The  underlying  pathophysiological  mechanisms  responsible  for  the  disease 
process seem to appear between 8 and 18 weeks of gestation (Robertson & Khong, 
1991).  But  the  signs  and  symptoms  become  apparent  in  relatively  late  stages  of 
pregnancy. So it is logical to search for predictive indicators. 
Measurement  in  early  pregnancy  of  a  variety  of  biological,  biochemical  and 
biophysical markers implicated in pathophysiology of preeclampsia has been proposed 
to predict  its  development.  Investigators have attempted to identify early markers of 
faulty  placentation,  reduced  placental  perfusion,  endothelial  cell  dysfunction  and 
activation of coagulation system. Attempts thus far have resulted in testing strategies 
with poor sensitivity and poor positive predictive value for preeclampsia. Currently there 
are no screening tests for preeclampsia that are reliable, valid and economical.
Some of the proposed predictive tests are:
1. Haemodynamic tests
a) Angiotensin II infusion test – Talledo et al. 1968.
By this test, abnormal vascular reactivity of patients destined to develop 
preeclampsia may be detected several weeks before clinical signs and 
symptoms  appear.  This  test  is  done  between  28  –  30  weeks.  
An  increase  in  the  diastolic  BP  more  than  20  mm  Hg   during  an 
Angiotensin infusion of 8 ng/ Kg or less predicts preeclampsia with a 
sensitivity of 90%, specificity of 87%, positive predictive value of 78% 
in  high  risk  population,  whereas  those  requiring  more  than  8  ng/Kg 
remain normotensive in 90%. 
b) Isometric hand grip test – Dagani et al. Suggested a threshold increase 
of  20  mm  Hg  in  diastolic  BP  when  patients  compresses   inflated 
sphygmomanometer cuff for a 3 min time. Sensitivity of this test is 81%, 
specificity 96%, positive predictive value 81%. This test is done between 
28 -32 weeks of gestation. 
c) Rollover test – This test is proposed by Grant et al. This test is done 
between 28 – 32 weeks of pregnancy. Blood pressure is first recorded with 
the patient in left lateral position. An increase in diastolic BP of more than 
20 mm Hg when the patient  lies  on the supine position is regarded as 
positive  test.  Sensitivity  varies  from  
0-88%,  specificity  5  -95%,  positive  predictive  value  
0-93%. This test is of no clinical use due to gross variation in results.
d) Mean Arterial Pressure – Page and Christianson suggested that patients 
with Mean Arterial Pressure more than 90 mm Hg in second trimester are 
at high risk for preeclampsia. But predictive values vary greatly. 
2. Doppler USG: Campbell and associates reported that Doppler velocimetry of 
uterine  umbilical  vessels  can  predict  preeclampsia  as  early  as  18  weeks. 
Patients  with  preeclampsia  had  a  characteristic  notching  of  diastolic 
waveform,  suggesting  increased  peripheral  resistance  due  to  impaired 
trophoblastic invasion of spiral arteries. Doppler may be useful to monitor the 
course of hypertensive disorders of pregnancy and the treatment effect, but it 
is not useful for screening pregnant women at low risk. Bower and colleagues 
1993,  used  a  two step  screening  test  beginning at  18  –  20  weeks  and its 
sensitivity  for  prediction  of  preeclampsia  was  78% but  positive  predictive 
value was only 28%.
3. URINARY ASSAYS :
a) Urinary calcium excretion 
b) Urinary calcium / creatinine ratio
c) Microalbuminuria
d) Urine Kallikrien / Creatinine ratio
e) Fasting urine albumin / creatinine ratio
4. MARKERS OF ENDOTHELIAL DYSFUNCTION:
a) Serum Fibronectin
b) Plasminogen  activator  inhibitors,  cell  adhesion  molecules,  serum 
thrombomodulin, endothelin 1.
c) Coagulation factors and Platelets
d) Serum uric acid
e) Others – atrial natriuretic peptide, haematocrit
Placental  functional  changes  in  the  form  of  increased  serum  βhCG(Human 
chorionic  gonadotrophin)  have  been  documented  and  several  prospective  studies 
indicate changes in the hormone which can be detected before the clinical diagnosis of 
preeclampsia. Several investigators have found that an elevated level of serum βhCG in 
early second trimester is a useful predictor of preeclampsia.
REVIEW OF LITERATURE
Preeclampsia and eclampsia remain a difficult puzzle to solve. Zweifel and later 
Chesley called it a disease of theories. Probably the oldest reference was in the Athvaida 
Veda, 200 BC. Mauriceau in 1668 stated that primigravidas were at a greater risk for 
convulsions  than  multigravidas. Demanent, 1797  suggested  oedema  as  a  cause  of 
convulsions in pregnancy. 
       Discovery of Proteinuria in preeclampsia was made by Lever and Simpson in 1843. 
In 1851, Frerichs published his work that eclampsia was a form of Uraemia. Fishberg, 
1899 regarded preeclampsia as a cause of essential hypertension.
Discovery of hypertension as a cause for eclampsia was restricted to Vaquez and 
Nabecourt in 1897.  Bassier (1790) first introduced the term “eclampsia”. De savages 
(1739), had differentiated convulsions of eclampsia from epilepsy. 
Castelli (1682), in his Lexicon medium, defined eclampsia as brightness lightning 
or shining of froth as in a flashing glance. 
Emma J Davidson, Simon C et al conducted retrospective study in a group of 
225 pregnant women who had PIH at term gestation. Their serum samples were tested at 
15 – 20 weeks for βhCG, activin, inhibin, alpha fetoprotein as predictors of PIH. Of 225 
women who had PIH at term, 24% of them had increased levels of βhCG at second 
trimester. 
Pankaj Desai, Sonal Rao et al conducted a study to find out whether βhCG can 
predict preeclampsia. Maternal serum βhCG at mid trimester was considered raised if 
levels were more than 2 multiples of median (MOM). 220 subjects were enrolled for the 
study.  They  were  completely  followed  up.  The  study  was  carried  out  between  
1995 – 2000, over a period of five years.  There were 90 mothers with serum βhCG 
levels  more  than  2  MOM  and  130  mothers  with  less  than  
2  MOM.  62  of  90  subjects  with  values  of  βhCG  more  than  
2 MOM(68.9%) developed PIH against 21 of 130 (16.15%) with the βhCG less than 2 
MOM.  59  out  of  62  who  developed  PIH  between  
28 –  32  weeks  had βhCG values  more  than  2  MOM. On the  other  hand 18 of  21 
(85.71%)  patients  who  developed  PIH  with  βhCG  less  than  
2 MOM did at  after  32 weeks.  In this  study it  was found that  βhCG was the most 
efficient in predicting preeclampsia remote from term.
      Tanya K Sorenson M.D.et al conducted a cohort study between 1990-1991. In this 
study,  180  women  had  elevated  βhCG  more  than  
2 MOM, 369 women had βhCG of less than 2 MOM. In 180 women who had βhCG 
more than 2 MOM, 71 women developed PIH with Proteinuria. The conclusion was that 
that the patients with increased βhCG values were at increased risk for preeclampsia 
(risk ratio 1.7, 95%, confidence interval 1.2-1.4). 
Jaiswar S P, Nisha et al did serum βhCG estimation by enzyme immuno-assay in 
162 pregnant women between 13-20 weeks of gestation. Of 162 women, 18 developed 
PIH. Those who developed PIH had serum βhCG ≥ 5000 µU / ml while 50% of those 
had serum βhCG more than 7000 µU/ml. Of 144 patients who remained normotensive, 
99.3% had βhCG less than 4000 µ U/ml, while 74.21% had βhCG levels between 2000 
to 3000 µU /ml.
R E Liepman, Williams et al conducted a cohort study of 460 women between 
Jan,  1990  and  Aug,  1991.  460  women  were  subjected  for  triple  screen  analysis 
(Maternal serum alpha fetoprotein, βhCG and unconjugated estradiol) between 15 – 18 
weeks of  gestation.  In  this,  1  in  195 had risk  for  Down syndrome.  Majority  of  the 
chromosomally normal singleton gestations without anomalies who had elevated βhCG 
developed PIH at term (68%) and had adverse pregnancy outcome. 
Feng Q and Cui S conducted a study and reported that serum βhCG maternal 
levels could reflect the degree of functional imbalance of trophoblast and it may be used 
as  clinical  detecting  index  of  PIH.  
On the other hand HPL (Human Placental Lactogen) is not such a useful factor.
Roiz –Hern and Cabello-Mart reported that measuring levels of βhCG during 
second trimester of pregnancy is useful in clinical practice to identify pregnant women 
who will develop preeclampsia.
Gonen et al and Sharg et al conducted a cohort analytical study to determine 
whether women with unexplained elevations of maternal serum βhCG at 16 – 20 weeks 
gestation are at an increased risk for pregnancy complications and adverse pregnancy 
outcome. The inclusion criteria were singleton gestation, confirmed gestational age and 
βhCG levels more than 2.5 MOM. The exclusion criteria were foetal  anomalies and 
maternal  serum  alphafeto  protein  (AFP)  more  than  2.5  MOM.  
A group of  randomly  selected  women with  normal  βhCG and maternal  serum AFP 
levels  served as control.  The results – of  6011 women screened 284 (4.7%) had an 
unexplained  elevated  HCG  levels.  Patients  with  elevated  levels  of  βhCG  had 
significantly higher risk for preeclampsia (Odds ratio 4.4, C.I. 1.9-10) and foetal growth 
restriction (Odds ratio 2.8, 95% CI 1-7).
Chandra S and Scott H studied 14,374 women during the period of 1994 – 2000 
and concluded that unexplained elevated levels of MSAFP / HCG were associated with 
increased  risk  of  most  pregnancy  complications.  Increased  antenatal  surveillance  of 
these patients is important.
Ashour  and  Lieberman conducted  a  study  to  investigate  the  association  of 
elevated second trimester serum βhCG concentration with subsequent development of 
preeclampsia.  They  examined  6286  non  diabetic  women with  singleton  pregnancies 
between 15 – 22 weeks of gestation (from Nov 1, 1991 - Nov 30, 1994). Women with 
pre-existing hypertension were excluded from the study. Beta HCG levels expressed as 
multiples  of  Median  (MOM)  adjusted  for  gestational  age  was  compared  between 
normotensive and hypertension complicating pregnant women.  They found increased 
incidence of preeclampsia in patients with raised serum βhCG levels.
PREECLAMPSIA
Preeclampsia is a disorder of unknown aetiology. It is a clinical syndrome rather 
than a single disease. Therefore the pathophysiologic abnormalities of this syndrome are 
heterogenous and vary among predisposed women. 
According  to  the  working  group  of  NHBPEP,  2000,  hypertensive  disorders 
complicating pregnancy are classified as follows:
1. Gestational hypertension (formerly PIH that included transient hypertension)
2. Preeclampsia
3. Eclampsia
4. Preeclampsia superimposed on chronic hypertension
5. Chronic hypertension
DEFINITION
Gestational hypertension:
 Blood pressure(BP) ≥ 140/90 mm Hg for first time during pregnancy
 No Proteinuria 
 BP returns to normal within 12 weeks post partum
 Final diagnosis made only postpartum
 May have other signs and symptoms of preeclampsia
          Preeclampsia:
          Minimum criteria:
 BP ≥ 140/90 mm Hg after 20 weeks of gestation
 Proteinuria ≥ 300 mg/24 h or ≥ 1+ dipstick
          Increased certainity of preeclampsia:
 BP ≥ 160/110 mm Hg
 Proteinuria 2g/ 24 h  or ≥ 2+ dipstick
 Serum creatinine > 1.2 mg/dl unless known to be previously elevated.
 Platelets < 1 lakh / cubic mm.
 Microangiopathic haemolysis (increased LDH).
 Elevated ALT/ AST
 Persistent headache or other cerebral or visual disturbance 
 Persistent epigastric pain 
Eclampsia:
          Seizures that cannot be attributed to other causes in a women with preeclampsia.
Superimposed preeclampsia on chronic hypertension
 New  onset  Proteinuria  ≥  300  mg/24  h  in  hypertensive  women  but  no 
Proteinuria before 20 weeks gestation.
 Sudden increase in proteinuria or blood pressure or platelet count < 1 Lakh / 
cubic  mm in  a  woman with hypertension  and proteinuria  before  20 weeks 
gestation. 
Chronic hypertension
 BP ≥ 140/90 mm Hg before pregnancy or diagnosed before 20 weeks gestation 
not attributable to gestational trophoblastic disease.
 Hypertension first diagnosed after 20 weeks of gestation and persistent after 12 
weeks postpartum.
ACOG CLASSIFICATION OF HYPERTENSION DURING PREGNANCY
1. Pregnancy induced hypertension
1.1 transient hypertension 
1.2 preeclampsia 
a) mild 
b) severe
1.3 eclampsia
2. Pregnancy aggravated hypertension
2.1 superimposed preeclampsia
2.2 superimposed Eclampsia
3. coincidental hypertension
INCIDENCE OF PREECLAMPSIA
Incidence  of  preeclampsia  is  5  –  8  %.  In  India  the  incidence  is  
7-9%.
RISK FACTORS FOR PREECLAMPSIA
1. extremes of age
2. nulliparity 
3. obstetric
 preeclampsia in previous pregnancy
 multiple gestation
 hydrops foetalis
 hydatidiform mole
4. pre-existing medical disorders
 hypertension
 diabetes mellitus 
 autoimmune disease
 thrombophilias
5. genetic 
 family history of preeclampsia
6. environmental 
FACTORS ASSOCIATED WITH REDUCED RISK OF HYPERTENSION
 Smoking
 Placenta previa
HYPERTENSION 
Hypertension during pregnancy is diagnosed when the resting BP is 140/ 90 mm 
Hg or greater. Korotkoff’s phase V is used to define diastolic pressure (Brown M A and 
Buddle M C, 1998). These BP recordings must be recorded on at least two occasions 6 
hours or more apart.
EDEMA
Edema is  abandoned  as  a  diagnostic  criterion,  because  it  occurs  in  too  many 
normal pregnant women. 
PROTEINURIA
     Proteinuria is an important sign of preeclampsia. Chesley, 1985 concluded that the 
diagnosis  of  preeclampsia  is  questionable  in  the  absence  of  proteinuria.  Significant 
proteinuria is defined by 24 hrs urinary protein exceeding 300 mg/ 24 hrs or persistent 
30  mg/dl  
(1+ dipstick)  in random urine sample.  Proteinuria is  commonly assessed by dipstick 
method.
Urinary dipstick Protein in urine
Trace 0.1 g /L
1 + 0.2 g/L
2+ 1 g/L
3+ 3 g/L
4+ 10 g/L
INDICATORS  OF  SEVERITY  OF  HYPERTENSIVE  DISORDERS  OF 
PREGNANCY
ABNORMALITY MILD SEVERE
Diastolic BP < 100 mm Hg ≥ 110 mm Hg
Proteinuria Trace – 1+ Persistent 
2+/more
Headache absent Present
Visual disturbance absent Present
Upper abdominal pain absent Present
oliguria absent Present
convulsions absent Present
Serum creatinine normal elevated
Thrombocytopenia absent Present
Liver enzyme elevation absent Present
Foetal growth restriction absent Present
Pulmonary oedema absent present
         
OTHER SYSTEMIC EFFECTS OF PREECLAMPSIA
BRAIN   : Oedema, haemorrhage, infarction
EYE  : Serous retinal detachment, cortical blindness, pappilloedema
          CVS      :   Hypertension, pulmonary oedema
RS          :  Pulmonary oedema, aspiration pneumonia
         LIVER     :  Congestion, haemorrhage, infarction, rupture
          KIDNEY:  Glomerulo endotheliosis, nephritic syndrome, acute renal failure
BLOOD:  Thrombocytopenia,  Microangiopathic  haemolytic 
anaemia, disseminated intravascular coagulation.
REPRODUCTIVE: IUGR, prematurity, placental abruption, foetal 
demise.
           SKIN  : Oedema, petechiae, ecchymosis
MUCOSA: Laryngeal oedema
AETIOLOGY OF PREECLAMPSIA
According to Sibai  (2003) currently  plausible  potential  causes of  preeclampsia 
include the following:
1. Abnormal trophoblastic invasion of uterine vessels
2. Immunological intolerance between maternal and feto-placental tissues
3. Maternal maladaptation to cardiovascular or inflammatory changes of normal 
pregnancy
4. Dietary deficiencies
5. Genetic influences
1. ABNORMAL TROPHOBLASTIC INVASION 
In normal implantation, the uterine spiral arteries undergo extensive remodelling 
as they are invaded by endovascular trophoblasts. In preeclampsia, there is incomplete 
trophoblastic  invasion.  In  this  case,  there  is  failure  of  second wave of  trophoblastic 
invasion.  The  decidual  vessels  but  not  myometrial  vessels  become  lined  with 
endovascular  trophoblast. Madazli and  colleagues  (2000)  showed that  magnitude  of 
defective  trophoblastic  invasion  of  spiral  arteries  correlated  with  severity  of 
hypertensive disorder.
Obstruction of spiral  arteriolar  lumen by atherosis may impair  placental  blood 
flow which eventually leads to preeclampsia syndrome (Lain and Roberts, 2002 and 
Redman, Sargent, 2003).
2. IMMUNOLOGICAL FACTORS 
There  is  circumstantial  evidence  to  support  the  theory  that  preeclampsia  is 
immune  mediated.  The  microscopic  changes  at  the  maternal  placental  interface  are 
suggestive  of  acute  graft  rejection  (Labarrere,  1988).  Risk  of  preeclampsia  is 
appreciably  enhanced  in  circumstances  where  formation  of  blocking  antibody  to 
placental  antigenic  sites  might  be  impaired.  This  may  arise  in  situations  in  which 
effective immunisation by a previous pregnancy is lacking as in first pregnancies or in 
which  the  number  of  antigenic  sites  provided  by  the  placenta  is  unusually  great 
compared with amount of antibodies as with multiple foetuses (Brer,1978).
Dekker  and  Sibai  (1998) have  reviewed  the  possible  role  of  immune 
maladaptation  in  the  pathophysiology  of  preeclampsia.  Beginning  in  early  second 
trimester,  women  destined  to  develop  preeclampsia  have  a  significantly  lower 
proportion  of  T  Helper  cells  
(  TH  1  )  compared  with  that  of  women  who  remain  normotensive  
( TH1 / TH2 imbalance).
3. VASCULOPATHY AND INFLAMMATORY CHANGES
In  response  to  placental  factors  released  by  ischaemic  changes  or  any  other 
inciting cause, cascades of events are set in motion (Redman and Sargent, 2003). The 
decidua also contains an abundance of cells that when activated can release noxious 
agents  (Staff  and  colleagues,  1999).  These  then  serve  as  mediators  to  provoke 
endothelial injury.
Redman and colleagues (1999) have proposed that endothelial cell dysfunction 
associated  with  preeclampsia  can  result  from  a  generalised  perturbation  of  normal 
maternal  intravascular  inflammatory  adaptation  to  pregnancy.  In  this  hypothesis, 
preeclampsia is considered as a disease due to an extreme state of activated leukocytes 
in maternal circulation. Oxidative stress is characterised by reactive oxygen species and 
free radicals that lead to formation of self propagating lipid peroxides (Manten and 
associates,  2005). These in turn generate highly toxic radicals that injure endothelial 
cells modifying their nitric oxide production and interfere with prostaglandin balance.
4. DIETARY DEFICIENCIES
Mac Gillivray reviewed the available evidence for role of dietary deficiency in 
the pathogenesis of preeclampsia. It was concluded that such available evidence was 
unsatisfactory. WHO expert committee on pregnancy and lactation concluded that there 
was no scientific basis for believing that either deficiencies or excess of any essential 
nutrient predisposes to preeclampsia. However the possibility does remain that in certain 
populations  there  may  be  specific  dietary  deficiency  that  may  predispose  to  or 
exacerbate the onset of preeclampsia.
When concentration of Calcium is low in extracellular fluid (ECF), the amount of 
ionic calcium entering the cell will increase, making vascular smooth muscle cells more 
sensitive  to  excitation  
(Ganong,1979).
Like calcium, decreased Magnesium levels are thought to potentiate contractile 
response of vascular smooth muscle to vasopressors (Prasad et al , 1980).
The role  of  dietary  deficiencies  e.g.  Calcium,  Magnesium,  Free  fatty  acids  in 
aetiology of hypertensive disorders of pregnancy still remains speculative.
5. GENETIC FACTORS  
The  predisposition  to  hereditary  hypertension  undoubtedly  is  linked  to 
preeclampsia (Nese and colleagues, 2003) and tendency of preeclampsia and eclampsia 
is highly heritable.  Kilpatrick and associates (1989) reported an association between 
histocompatibility antigen (HLA- DR4) and proteinuric hypertension.
PATHOGENESIS OF PREECLAMPSIA
 VASOSPASM
The concept  of  vasospasm was  advanced  by  Volhard  (1918)  based  on direct 
observation of small blood vessels in nail beds, ocular fundi and bulbar conjunctiva. 
Endothelial  cell  damage causes  interstitial  leakage  through which blood constituents 
including platelets and fibrinogen are deposited subendothelially. 
ENDOTHELIAL CELL ACTIVATION
Over the past two decades endothelial cell activation has become the centre piece 
in  contemporary  understanding  of  pathogenesis  of  preeclampsia.  In  this  scheme, 
unknown factors likely from placenta are secreted in to the maternal circulation and 
provoke activation & dysfunction of vascular endothelium. The clinical syndrome of 
preeclampsia is thought to result from these widespread endothelial cell changes.
INCREASED PRESSOR RESPONSES
      Women with  early  preeclampsia  have  increased  vascular  reactivity  to  infused 
norepinephrine and Angiotensin II. 
       Prostaglandins : When compared to normal pregnancy, endothelial prostacyclin 
(PG I2) production is decreased in preeclampsia. At the same time, Thrombaxane A2 
(TXA2) secretion by platelets is increased and PG I2 / TXA2 ratio decreases.
       Nitric oxide : Nitric oxide (NO) previously termed endothelial derived relaxing 
factor  (EDRF)  is  synthesised  by  endothelial  cells  from  L-Arginine  (Palmer  and 
associates, 1988). It is a potent dilator whose absence or decreased concentration might 
play  a  role  in  the  aetiology  
of PIH. 
Endothelins: These  21  aminoacid  peptides  are  potent  vasoconstrictors  and 
endothelin-1 (ET1) is primary isoform produced by human endothelium (Mastrogiannis 
and co-workers, 1997).
Plasma endothelin-1 is increased in normotensive pregnant women but women 
with preeclampsia have even higher levels.
ANGIOGENIC FACTORS
Several glycosylated glycoproteins are selectively angiogenic and are thought to 
be important in mediating preeclampsia syndrome. Two of these are VEGF (Vascular 
endothelial growth factor) and PLGF (platelet growth factor). 
HUMAN CHORIONIC GONADOTROPHIN 
(hCG)
Human chorionic gonadotrophin is a glycoprotein, a peptide framework to which 
carbohydrate side chains are attached. Half life of hCG is 24 hours. HCG consist of 2 
subunits,  non-covalently  linked  by  disulphide  bonds,  called  alpha  and  beta.  The  α 
subunit is identical to FSH, LH, TSH and consist of 92 aminoacids. Unique biological 
activity  as  well  as  specificity  in  immunoassays  is  attributed  to  the  molecular  and 
carbohydrate  differences  in  β  subunit.  The  β  subunit  contains  a  larger  carbohydrate 
moiety and 145 amino acid residues including a unique carboxy terminal tail piece of 23 
amino acid groups. It is this unique part of HCG structure that allows production of 
highly specific antibodies and utilization of highly specific immunological assays.
        HCG is mainly synthesized by syncytiotrophoblasts. The maternal circulating HCG 
concentration is approximately 100 IU/L at the time of expected but missed menses. The 
maximum  level  of  about  1,00,000  
IU /L in maternal circulation is reached at 8 – 10 weeks gestation. HCG levels decrease 
to about 10,000 – 20,000 IU / L by 18-20 weeks of gestation and remain at that level 
until delivery. 
All human tissues appear to  make HCG in small amounts but the placenta is 
different  in  having  the  ability  to  glycosylate  the  protein,  thus  reducing  the  rate  of 
metabolism and giving it biological activity through long half life. HCG produced in 
sites other than placenta has little or no carbohydrate moiety and therefore it has a very 
short half life and rapidly clears from the circulation through the kidneys.
HCG becomes detectable in maternal serum as early as 8 -10 days after ovulation 
in normal conception cycles.  In a normally progressing early intrauterine pregnancy, 
βhCG levels should increase at least 66% every 48 hours at concentration below 10,000 
IU/L.
Biosynthesis of HCG:  (Genetics of HCG) 
The  alpha  subunit  originates  from  one  single  gene  
 in chromosome 6, the beta subunits are from chromosome 19. There are 8 separate 
genes for beta subunits of different glycoprotein hormones. 
REGULATION OF HCG SYNTHESIS
HCG secretion is probably regulated by the following factors, although the exact 
mechanism has not yet been identified. 
1. Placental  GnRH  (  Gonadotrophin  releasing  hormone)  and  CRH  
(Corticotrophin releasing hormone)
2. Butyrated cyclic AMP 
3. Interleukin – 1 and interleukin – 6
4. Tumour necrosis factor (TNF)
5. Trophoblastic Growth Factor ( TGF –B)
6. Fibroblast Growth Factor 
FUNCTIONS OF HCG 
1. Both subunits of HCG have a binding tendency to the LH / HCG receptor. It is this 
binding that is most marked in the tissues of corpus luteum
2. Rescue of corpus luteum  -  Soon after embedding of the ovum, the fertilized ovum 
needs  a  support  for  survival  for  which continued Progesterone is  necessary.  The 
Progesterone at this stage of pregnancy is available only from corpus luteum. Hence 
the  life  of  the  corpus  luteum needs  to  be  prolonged  beyond  2  weeks  after  the 
expected date of menstruation and this prolongation of the life of corpus luteum is 
provided by the HCG and probably is the only explanation of HCG function in the 
early pregnancy
3. HCG promotes relaxin secretion by the corpus luteum. Further HCG is also believed 
to promote vascular dilatation and myometrial relaxation providing support to the 
fertilized ovum.  
NORMAL SERUM βhCG VALUES IN PREGNANCY
GESTATIONAL 
AGE
weeks
MEDIAN
IU/ ml.
RANGE
IU /ml.
4 1.1 0.04 – 4.48
5 8.05 0.27 – 28.7
6 29.7 3.7 – 84.9
7 58.8 9.7 – 120
8 79.5 31.0 – 184
9 91.51 61.5 – 182
10 71.01 22.0 – 143
14 34.91 15.0 - 92
15 26.81 10.6 – 64.2
16 21.2 9 – 52.8
17 19.1 6.7 – 47.1
18 15.6 6.1 – 42.1
19 15.2 6.8 – 45.9
20 15.1 6.3 – 44
ELISA (ENZYME LINKED IMMUNOSORBANT ASSAY)
It is useful for quantification of extremely small amounts of βhCG. ELISA test 
uses monoclonal antibodies bound to a solid phase support which binds the βhCG in the 
sample.  A second antibody is added to sandwich the test  sample βhCG. The second 
antibody is linked with an enzyme such as Alkaline Phosphatase. When the substrate for 
this enzyme is added, blue colour develops. The intensity of which is proportional to the 
amount of enzyme and thus to the amount of second antibody bound. This in turn is a 
function of the amount of βhCG in the test sample. The sensitivity of the test is 25 – 50 
mU/ml. 
AIM OF STUDY   
1. To estimate Serum β hCG levels in early 2nd trimester in a population of high risk 
Multigravid women 
2.  To  study  any  positive  correlation  between  elevated  serum  βhCG  and  the 
development of preeclampsia.
MATERIALS AND METHODS
Study design: Prospective case control study 
Study place: Institute of Obstetrics and Gynaecology, Egmore, Chennai.
Study period:  April, 2007 – April, 2008. 
      This study was conducted in 200 cases of high risk multi gravid women attending 
outpatient department of Institute of Obstetrics and Gynaecology, Chennai.
     This study was approved by the board of ethical committee.
METHODOLOGY
         200 cases of high risk multigravid women attending outpatient department of IOG 
with normal blood pressure and normal urine examination of gestational age 15 – 20 
weeks were taken for the study after obtaining informed consent. The high risk factors 
included in the study were previous history of preeclampsia remote from term(< 34 
weeks),  recurrent  spontaneous abortions (2 or  more),  previous still  births,  accidental 
haemorrhage,  IUGR, eclampsia.  Detailed history and physical  examination including 
blood  pressure,  urine  examination,  and  abdominal  examination  were  done.  Other 
baseline investigations like Hb, PCV, blood sugar, USG were done to rule out anaemia, 
diabetes,  multiple  pregnancies,  anomalous  babies  and  wrong  dates.  About  5  ml  of 
venous blood was taken at 15 to 20 weeks gestation and serum βhCG estimated by 
ELISA method using Chemiluscence technique. Patients were divided into two groups 
based on their serum βhCG values – 1) those with elevated serum βhCG (≥2 MOM)   2) 
those  with  normal  serum  βhCG  values  (<2  MOM).  Both  groups  of  patients  were 
followed up fortnightly up to 28 weeks and then weekly till delivery. During each visit 
general  examination including blood pressure recording,  urine examination for  sugar 
and protein,  abdominal  examination  to  assess  foetal  growth & wellbeing and liquor 
status were done.
         To ensure accurate reading of blood pressure and appropriate size BP cuff was 
used (12 x 23 cm for normal size arm and for arm size more than 35 cm cuff size 15 x 
33 cm). BP was recorded after a rest period of 10 min., with the patient in sitting posture 
with the arm at the level of heart.
          The results were analysed using Chi-square and two sample t test using SPSS 
version 11.5 software.
INCLUSION CRITERIA
         Multigravid women with previous history of 
i. PIH remote from term (less than 34 weeks)
ii. Recurrent spontaneous abortion (two or more)
iii. Still birth 
iv. Accidental haemorrhage
v. IUGR
vi. Eclampsia.
EXCLUSION CRITERIA
a. Gestational age < 15 weeks or >20 weeks 
b. Women with Chronic hypertension
c. Other medical disorders complicating pregnancy such as Diabetes, Anaemia, 
Thyroid, SLE.
d. Multiple pregnancies
e. Babies with suspected or confirmed congenital anomalies detected by USG  
                                  
RESULTS
TABLE-1  :   AGE GROUP 
Age group No. Of cases Percent
<  20 years 6 3
21  - 25 99 49.5
26 – 30 95 47.5
TOTAL 200 100
Majority of cases were in the age group of 21 – 25 years (49.5%). Only 6 cases 
were in the age group of < 20 years.
AGE  DISTRIBUTION  IN  RELATION  TO  DEVELOPMENT  OF 
PREECLAMPSIA
AGE GROUP
NO. OF CASES THAT 
DEVELOPED 
PREECLAMPSIA
PERCENTAGE
< 20 YEARS 6 6.38%
21 – 25 YEARS 41 43.62%
26 – 30 YEARS 47 50%
              
 Majority of cases that developed preeclampsia belonged to the age group of 26 – 30 
years  (50%).  All  6  cases  in  the  age  group  of  
≤ 20 years developed preeclampsia. 
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TABLE-2 : SOCIOECONOMIC STATUS
SOCIO ECONOMIC 
CLASS
NO.OF CASES PERCENTAGE
III 4 2
IV 31 15.5
V 165 82.5
Most of the cases (82.5%) belonged to socioeconomic class V. This is an expected one 
as our hospital serves very low socioeconomic class patients.
SOCIOECONOMIC  CLASS  IN  RELATION  TO  DEVELOPMENT  OF 
PREECLAMPSIA
SOCIOECONOMIC 
CLASS
NO. OF CASES THAT 
DEVELOPED 
PREECLAMPSIA
PERCENTAGE
III 4 4.25
IV 23 24.46
V 67 71.27
Most of the cases that developed preeclampsia also belonged to socioeconomic 
class V (71.27%).
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TABLE -3 :  PARITY 
GRAVIDA NO. OF CASES PERCENTAGE
2 113 56.5
3 63 33
4 18 9
5 3 1.5
About 56.5% of cases were second gravidae; only 1.5% of cases were gravida 5.
PARITY IN RELATION TO PREECLAMPSIA
GRAVIDA
NO. OF CASES 
THAT DEVELOPED 
PREECLAMPSIA
PERCENTAGE
GRAVIDA 2 58 61.70%
GRAVIDA 3 28 29.79%
GRAVIDA 4 7 7.45%
GRAVIDA 5 1 1.06%
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About 61.70% of cases that developed preeclampsia were of gravida 2. 
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TABLE - 4 : DISTRIBUTION OF GESTATIONAL AGE AT WHICH BLOOD 
SAMPLE FOR SERUM βhCG WAS TAKEN
GESTATIONAL AGE 
IN WEEKS
NO.OF CASES PERCENTAGE
15 7 3.5%
16 94 47%
17 56 28%
18 32 16%
19 6 3%
20 5 2.5%
Majority  of  the blood samples  were taken at  the gestational  age of  16 weeks 
(47%).
Percentage of  Cases
15 weeks
16 weeks
17 weeks
18 weeks
19 weeks
20 weeks
TABLE - 5  :  COMPARISON OF GESTATIONAL AGE AT WHICH SERUM 
βhCG  WAS  TAKEN  BETWEEN  THE  NORMAL  AND  ELEVATED  HCG 
GROUPS
SERUM βhCG NO. OF CASES
MEAN 
GESTATIONAL AGE
≥2 MOM 106 16.7075
<2 MOM 94 16.8085
P = 0.490 (NOT SIGNIFICANT).
There was no statistically significant difference in gestational age at which serum 
βhCG  was  taken  between  the  normal  and  elevated  
βhCG groups.
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TABLE  -  6:  COMPARISON  OF  DEVELOPMENT  OF  PREECLAMPSIA 
BETWEEN NORMAL AND ELEVATED  HCG GROUPS
SERUM β HCG
≥2 MOM <2 MOM
TOTAL
PREECLAMPSIA + 76  (71.7%) 18 (19.1%) 94
PREECLAMPSIA - 30 (28.3) 76(80.9%) 106
TOTAL 106 94 200
P = <0.001(SIGNIFICANT)
Out  of  106  cases  with  elevated  serum  βhCG  values  76  patients  developed 
preeclampsia (71.7%). This is in contrast to 94 cases with normal βhCG values of which 
only 18 cases (19.1%) developed preeclampsia. This is statistically significant with P 
value  less  
than 0.001.
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EVALUATION OF SERUM βhCG AS A SCREENING TEST IN PREDICTING 
PREECLAMPSIA:
SERUM βhCG
PREECLAMPSIA
YES NO
TOTAL
≥2 MOM 76 (a) 30 (b) 106
<2 MOM 18 (c) 76 (d) 94
Sensitivity = a / a+c x 100 = 76 / 76+18 x 100 = 80.85%
Specificity = b / b+d x 100 = 30 /30+76 x 100 = 71.7%
Positive predictive value = a / a+b x 100 = 76 / 76+30 x 100 = 71.7%
Negative predictive value = d/ c+d x 100 = 76 /76+18 x 100 = 80.85%
Diagnostic accuracy of the test is 76% (Wilson’s score).
Thus evaluation of serum βhCG at 15 – 20 weeks of gestation predicts preeclampsia 
with  a  sensitivity  of  80.85%,  specificity  of  71.7%,  and positive  predictive  value  of 
71.7% and negative predictive value of 80.85%.
TABLE-7: COMPARISON  OF  GESTATIONAL  AGE  AT  WHICH 
PREECLAMPSIA DEVELOPED BETWEEN THE NORMAL AND ELEVATED 
HCG GROUPS
SERUM 
β HCG
NO. OF CASES 
THAT DEVELOPED 
PREECLAMPSIA
MEAN GESTATIONAL 
AGE AT WHICH 
PREECLAMPSIA 
DEVELOPED
≥2 MOM 76 34.9737
<2 MOM 18 36.1667
P = 0.035 (SIGNIFICANT)
The average gestational  age at  which preeclampsia  developed in patients  with 
elevated serum βhCG was 34.97 weeks. This is significantly earlier when compared to 
the average gestational age of 36.16 weeks at which preeclampsia developed in patients 
with normal serum βhCG values.
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TABLE-8  :  COMPARISON  OF  DEVELOPMENT  OF  COMPLICATIONS 
BETWEEN THE NORMAL AND ELEVATED HCG GROUPS:
COMPLICATIONS
SERUM β HCG
≥2 MOM <2 MOM
TOTAL
NO COMPLICATIONS 97 (91.5%) 92 (97.9%) 189
ABRUPTION 2 (1.9%) 0 (0.0%) 2
ECLAMPSIA 2 (1.9%) 1 (1.1%) 3
HELLP 1 (0.9%) 0 (0.0%) 1
IUGR 3 (2.8%) 1 (1.1%) 4
PUL. EDEMA 1 (0.9%) 0 (0.0%) 1
                                    P=1.000 (NOT SIGNIFICANT)
Of the 11 complications that developed totally only 2(18.18%) were in the normal 
serum βhCG group. Remaining 9 (81.82%) were in the elevated serum βhCG group.
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 TABLE-9  :  COMPARISON  OF  GESTATIONAL  AGE  AT  DELIVERY 
BETWEEN THE NORMAL AND ELEVATED HCG  GROUPS
GESTATIONAL AGE 
AT DELIVERY
SERUM βhCG
≥2 MOM <2 MOM
TOTAL
PRETERM (<37 WEEKS) 5 (4.72%) 3 (3.19%) 8
TERM ( ≥ 37 WEEKS) 101 (95.28%) 91(96.81%) 192
TOTAL 106 94 200
 
P = 0.752[NOT SIGNIFICANT]
No  significant  difference  was  found  in  the  incidence  of  preterm  deliveries 
between the normal and elevated βhCG groups.
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TABLE-10  :  COMPARISON  OF  AVERAGE  GESTATIONAL  AGE  AT 
DELIVERY BETWEEN THE NORMAL AND ELEVATED HCG GROUPS
SERUM βhCG NO.OF CASES
MEAN GESTATIONAL 
AGE AT DELIVERY
In WEEKS
≥2 MOM 106 38.5000
<2 MOM 94 39.5426
P = 0.001 (SIGNIFICANT)
The average gestational age at delivery was 38.5 weeks in patients with elevated 
serum βhCG values and 39.5 weeks in patients with normal serum βhCG values. This is 
statistically significant.
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TABLE  -  11  :  COMPARISON  OF  MODE  OF  DELIVERY  BETWEEN  THE 
NORMAL AND ELEVATED  HCG GROUPS
MODE OF 
DELIVERY
SERUM βhCG
≥2 MOM <2 MOM
TOTAL
SPONTANEOUS 
VAGINAL 
DELIVERY
58 (54.7%) 54 (57.4%) 112
INSTRUMENTAL 
VAGINAL 
DELIVERY
3 (2.8%) 1 (1.1%) 4
LSCS 45 (42.5%) 39 (41.5%) 84
TOTAL 106 94 200
P = 0.652 (NOT SIGNIFICANT).
There was no statistically significant difference in the mode of delivery between 
the normal and elevated serum βhCG groups.
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TABLE-12:  COMPARISON  OF  MEAN  BIRTH  WEIGHT  BETWEEN  THE 
NORMAL AND ELEVATED HCG GROUPS
SERUM βhCG NO. OF CASES
MEAN BIRTH 
WEIGHT
≥2 MOM 106 2.800
<2 MOM 94 2.9038
P = 0.042 (SIGNIFICANT)
The average birth weight for patients with elevated serum βhCG values was 2.8 
weeks when compared to 2.9 weeks in patients with normal serum βhCG values. This is 
statistically significant.
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TABLE-13: COMPARISON OF BIRTH WEIGHT BETWEEN THE NORMAL 
AND ELEVATED HCG GROUPS
BIRTH WEIGHT
SERUM βhCG
≥2 MOM <2 MOM
TOTAL
≥2.5 Kg 82 (77.4%) 78 (83.0%) 160
<2.5 Kg 24 (22.6%) 16 (17.0%) 40
TOTAL 106 94 200
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TABLE-14: COMPARISON OF 5-MINUTE APGAR BETWEEN THE NORMAL 
AND ELEVATED  HCG GROUPS:
APGAR
SERUM βhCG
≥2 MOM <2 MOM
TOTAL
0 2 (1.9%) 0 (0.00%) 2
≥7 95 (89.6%) 90 (95.7%) 185
<7 9 (8.5%) 4 (4.3%) 13
P = 0.187 (NOT SIGNIFICANT)
Out  of  13  cases  with  less  than  score  7  of  five  minute  APGAR,  
9 were from elevated serum βhCG group and 4 from normal serum βhCG group. There 
were 2 still born babies in elevated HCG group and none in normal HCG group.
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TABLE-15: COMPARISON OF NICU ADMISSION BETWEEN THE NORMAL 
AND ELEVATED HCG GROUPS
NICU 
ADMISSION
SERUM βhCG
≥2 MOM <2 MOM
TOTAL
NO 96 (90.6%) 87 (92.6%) 183
YES 10 (9.4%) 7 (7.4%) 17
TOTAL 106 94 200
P = 0.800 (NOT SIGNIFICANT)
Out of 17 babies admitted in NICU, 10 babies (58.82%) were from elevated HCG 
group and 7(41.17%) from normal HCG group. This is not statistically significant.
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TABLE-16:  COMPARISON  OF  NEONATAL  DEATHS  BETWEEN  THE 
NORMAL AND ELEVATED  HCG GROUPS 
NEONATAL 
OUTCOME
SERUM βhCG
≥2 MOM <2 MOM
TOTAL
NO DEATH 101 (95.3%) 93 (98.9%) 194
NEONATAL DEATH 5 (4.7%) 1 (1.1%) 6
TOTAL 106 94 200
P = 0.217 (NOT SIGNIFICANT).
There were 6 neonatal deaths of which 5 were in the elevated serum βhCG group 
and only 1 in normal HCG group. This is not statistically significant.
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TABLE-17:  COMPARISON  OF  MATERNAL  DEATH  BETWEEN  THE 
NORMAL AND ELEVATED HCG GROUPS
MATERNAL DEATH
SERUM βhCG
≥2 MOM <2 MOM
TOTAL
NO DEATH 105 (99.1%) 94 (100%) 199
MATERNAL DEATH 1 (0.9%) 0 (0.0%) 1
TOTAL 106 94 200
P = 1.00 (NOT SIGNIFICANT)
There was only one maternal death. It was in the elevated serum βhCG group.
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DISCUSSION
Table 1 and 2: of the 200 patients in this study majority of women were in the age 
group of 20 to 25 years and 26 to 30 years. The mean age of the patients taken for this 
study was 25 years. 
About  82.5%  of  women  belonged  to  socioeconomic  class  v.  
This is an expected one as our hospital serves mainly very low income group women. 
Table  3: Only  high  risk  multigravidas  were  taken  for  this  study.  Fawaz 
Alkazaleh et al. suggested that maternal serum screening including βhCG be confined 
to cohorts of clinically high risk women. This view is also reinforced by a recent French 
study,  screening 2615 unselected women with maternal  serum screening and uterine 
artery  Doppler  in  second  trimester  for  adverse  pregnancy  outcomes  including 
preeclampsia which concluded that this approach was of no clinical benefit in low risk 
patients. 
Table 4 & 5 : Serum beta hCG was measured in high risk multigravidas at 15 – 20 
weeks of gestation in this study.
Nathalie Lepage and David Chitayat et al., conducted a study in a group of 564 
women  with  singleton  pregnancies.  They  estimated  serum  βhCG  at  15-20  weeks 
gestation and concluded that high maternal serum βhCG values were associated with an 
increased risk of adverse pregnancy outcomes including preeclampsia. 
Table 6, 7 and 8  : In a study conducted by  Yuval Yaron et al., and Michele 
Cherry et al., it was found that patients with increased serum βhCG (≥ 2.5 MOM) were 
significantly  at  high  risk  of  pregnancy  induced  hypertension  with  proteinuria, 
miscarriage, and intrauterine foetal death. They estimated maternal serum βhCG levels 
in  45,565  patients  over  a  five  year  period  (  March,1991-May,1996)  and  compared 
pregnancy outcomes in patients with normal HCG  and elevated HCG values. 
Sorensan  et  al  found  that  increased  maternal  serum  βhCG
(more  than  2  MOM) was associated  with  significant  increase  in  pregnancy  induced 
hypertension (risk ratio 1.7) and proteinuric pregnancy induced hypertension (risk ratio 
5.1).  They  suggested  that  hypoperfusion  of  placental  villi  leads  to  increased  βhCG 
production. Such changes would also predispose to adverse outcome such as miscarriage 
and intrauterine foetal death.  
The Ontario  maternal  serum  screening  program which  was  conducted  to 
examine the clinical significance of high maternal serum βhCG in second trimester in 
singleton  and twin pregnancies  also  showed that  women with singleton  pregnancies 
having elevated serum HCG had increased adverse obstetric outcomes (22.5% severe 
adverse obstetric outcomes compared with only 10.9% of matched controlled population 
P = 0.001) including preeclampsia, antepartum haemorrhage, small for gestational age 
babies, preterm deliveries and miscarriages. 
Benn et al reported that when maternal serum βhCG is more than 3 MOM, the 
incidence of  preeclampsia,  low birth  weight  babies,  foetal  and neonatal  deaths were 
increased significantly. 
Valiant  et  al.,  David  E  et  al., found  that  there  is  increased  incidence  of 
preeclampsia in patients with elevated maternal serum βhCG levels at 14 – 20 weeks 
gestation with sensitivity of 66.7%, specificity 98%, positive predictive value of 61.4% 
and negative predictive value 97.3%.
The Results of this study also shows that patients with elevated maternal serum 
βhCG levels were associated with increased incidence of preeclampsia and other adverse 
obstetric outcomes. In this study the sensitivity of βhCG in predicting preeclampsia was 
found to be 80.85%, specificity 71.7%, positive predictive value 71.7% and negative 
predictive value 80.85% with diagnostic accuracy of 76%.
       Table  9  & 10: Patients  with  elevated  serum βhCG had  significantly  earlier 
deliveries  (mean  gestational  age  at  delivery  38.5  weeks)  compared  to  patients  with 
normal βhCG values (Mean gestational age at delivery 39.54 weeks) although there was 
no significant difference between preterm and term deliveries.
Wenstrom et al., evaluated elevated serum βhCG values in second trimester and 
found that there is an increased incidence of preterm delivery and other adverse foetal 
and neonatal outcomes.
Table 11:  no difference was observed in the mode of delivery between the group 
of patients with normal and elevated βhCG values. 
Table 12 &13 : Liepman et al., reported that there is increased risk for low birth 
weight  babies  (risk  ratio  4.0),  preterm  delivery  
(risk ratio 2.8), and IUGR (RR 1.8) in patients with elevated mid trimester serum βhCG 
values.
Morssink et  al., studied the relationship between abnormal levels  of maternal 
serum βhCG and adverse pregnancy outcomes. They found that small for gestational age 
babies were associated with isolated high maternal serum HCG levels (more than or 
equal to 2.5 MOM).
 Ganapathy  R,  Lamont  R  F  et  al., reported  that  Mean  Birth  Weight  was 
significantly lower in group with elevated maternal serum HCG. 
Miyakoshi et al., reported that elevated levels of second trimester maternal serum 
hCG were as sensitive and specific in predicting SGA babies as abnormal uterine artery 
Doppler velocimetry .
In this study there was a signi0ficant difference in birth weight between the two 
HCG groups.  The  mean  birth  weight  in  normal  HCG values  was  2.800  Kg and in 
patients with elevated HCG values was 2.9038 Kg with a P value of 0.042.
Table 14, 15, 16 and 17:  Miluensky et al noted that elevated maternal serum 
HCG levels were associated with adverse foetal and neonatal outcomes.
Owen J and Boots L R reported that elevated HCG values similar to unexplained 
elevated  maternal  serum alpha  feto  protein are  significantly  associated  with  adverse 
neonatal outcomes.
Perez et al, and David et al also reported that increased incidence of adverse 
neonatal outcomes in patients with isolated elevation of second trimester maternal serum 
HCG levels and pregnancies with unexplained elevated HCG values should be regarded 
as high risk pregnancies and managed accordingly.
Gravett et al also concluded from his study that raised midtrimester maternal 
serum  HCG  may  be  an  independent  risk  factor  for  subsequent  adverse  pregnancy 
outcomes.
In this study there was no significant difference observed in the 5 minute APGAR, 
NICU admission, Neonatal Death and maternal death in patients with elevated HCG as 
compared to patients with normal HCG values.
  
SUMMARY
 This study was conducted in 200 cases of high risk multigravid women to evaluate 
the validity of midtrimester serum βhCG in predicting preeclampsia.
 Majority of women in this study were in the age group of 21 – 25 years (49.5%) and 
of socioeconomic class v (82.5%)
 Majority of women were second gravidae (56.5%).
 The average gestational age at which serum βhCG was taken was 16 weeks.
 Of 106 cases with elevated serum βhCG (≥2 Multiples of Median), 76 cases (71.7%) 
developed preeclampsia. This is in contrast to 94 cases with normal HCG values, of 
whom 18cases (19.9%) developed preeclampsia. This is statistically significant with 
P value < 0.001.
 Preeclamptic  patients  with  elevated  serum βhCG  values  developed  preeclampsia 
significantly  earlier (average 34.97 weeks)  in gestation than preeclamptic patients 
(36.16 weeks) with normal serum βhCG values.
 Out  of  106  patients  with  elevated  serum  βhCG  values  9  patients  developed 
complications as compared to 94 patients with normal serum βhCG values of which 
only 2 patients developed complications.
 Patients with elevated serum βhCG values also had significantly earlier deliveries 
and lower birth weight babies when compared to normal serum βhCG group.
CONCLUSION
Preeclampsia is  a multisystem disorder  of  unknown aetiology.  Although many 
predictors have been put forth none of the methods so far described have been very 
much  sensitive  and  specific  to  predict  the  development  of  preeclampsia.  Predicting 
preeclampsia at an early gestational age helps us to monitor the patients closely and 
detect  development  of  preeclampsia  earlier  and  thereby  reducing  the  maternal  and 
perinatal mortality and morbidity. Estimating midtrimester (15 – 20 weeks) serum βhCG 
is a useful method in predicting preeclampsia in high risk multigravid women as it is a 
non invasive simple method with sensitivity of 80.85%, specificity of 71.7%, positive 
predictive  value of  71.7% and negative  predictive value  of  80.85% ,  the diagnostic 
accuracy of the test is 76% (Wilson’s score). The disadvantage of using serum βhCG in 
predicting preeclampsia is its cost and low sensitivity in nulliparous women.
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                         PROFORMA
Date:
Name:
Age:
IP no:
Address:
Socioeconomic status:
Booked/ un booked:
Immunised / non-immunised
Obstetric score: 
LMP:
EDD:
Gestational age:
Any associated medical complications:
Previous obstetric history:
a) History of recurrent abortions (2 or more)
b) Previous history of Preeclampsia remote from term (less than 34 weeks)
c) Previous history of abruption
d) Previous history of IUGR
e) Previous history of eclampsia
f) Previous history of stillbirth
Family history:
Personal history:
Symptoms:
Clinical examination:
     GENERAL EXAMINATION
a) Height
b) Weight
c) BP
d) Pedal oedema
e) Pallor +/-
CVS: 
RS:
Per abdominal examination:  
 Fundal height
 Foetal heart rate
 Adequacy of liquor
 presentation
      INVESTIGATIONS:
 Urine  - Albumin, Sugar
 Haemoglobin, PCV
 Blood – urea, sugar, creatinine
 USG :  
 Serum βhCG
  TREATMENT GIVEN:
   GESTATIONAL AGE AT DELIVERY:
 TYPE OF LABOUR - Spontaneous / induced
  MODE  OF  DELIVERY  –  spontaneous  vaginal  delivery,  caesarean  section, 
instrumental vaginal delivery
  Adverse maternal outcome – if any
  Birth weight of baby: 1. ≥ 2.5 kg      2. < 2.5 Kg.                                        
  APGAR: 1. 5 minute APGAR ≥ 7     2. 5 minute APGAR < 7
3. 0 – dead born
  NICU admission:  YES / NO  
   Foetal outcome:   alive / dead
                                    
